Clovis Oncology: Rubraca ovarian cancer drug now available in Spain

Clovis Oncology: Rubraca ovarian cancer drug now available in Spain

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced Rubraca (rucaparib) is now available and reimbursed in Spain following the Spanish Interministerial Commission on Prices of... Read More

Monday March 2, 2020 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick Mahaffy

Clovis Oncology announces Rubraca cancer drug available in France

Clovis Oncology announces Rubraca cancer drug available in France

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca (rucaparib) is now available and reimbursed in France. Rubraca is an option for monotherapy maintenance treatment... Read More

Monday February 3, 2020 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy

Clovis Oncology’s Rubraca granted FDA priority review for advanced prostate cancer

Clovis Oncology’s Rubraca granted FDA priority review for advanced prostate cancer

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the U.S. Food and Drug Administration (FDA) has accepted the companys supplemental New Drug Application (sNDA) for Rubraca ... Read More

Wednesday January 15, 2020 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffey, Rubraca

Colorado life sciences companies raise $750M in 2019, Pfizer acquisition of Array BioPharma brings total to $12.1B

Colorado life sciences companies raise $750M in 2019, Pfizer acquisition of Array BioPharma brings total to $12.1B

DENVER -- Colorados life sciences ecosystem raised $750 million in 2019, with funds from federal and state grants, successful financing rounds and acquisitions. The record-breaking acquisition of... Read More

Wednesday December 18, 2019 0 comments Tags: Denver, Colorado BioScience Association, Jennifer Jones Paton, Array BioPharma, Clovis Oncology, Inscripta, Emily Roberts

Clovis: Rucaparib recommended for United Kingdom women with relapsed ovarian cancer

Clovis: Rucaparib recommended for United Kingdom women with relapsed ovarian cancer

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced the National Institute for Health and Care Excellence (NICE) has recommended that women with relapsed ovarian cancer in England have... Read More

Monday October 14, 2019 0 comments Tags: Boulder, Clovis Oncology, Rucaparib, Patrick J. Mahaffey

Clovis updates data on Rubraca clinical trial

Clovis updates data on Rubraca clinical trial

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) announced updated data from the Phase 2 TRITON2 trial at the European Society for Medical Oncology (ESMO) Congress 2019, reinforcing the... Read More

Monday September 30, 2019 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy

Clovis to collaborate with German biotech company

Clovis to collaborate with German biotech company

BOULDER/BERLIN -- Clovis Oncology, Inc. (NASDAQ: CLVS) announced it has entered into a global licensing and collaboration agreement with 3B Pharmaceuticals GmbH (3BP), a private German... Read More

Tuesday September 24, 2019 0 comments Tags: Boulder, Clovis Oncology, 3B Pharmaceuticals, Patrick Mahaffy

Clovis Oncology to offer $225M in convertible senior notes to investors

Clovis Oncology to offer $225M in convertible senior notes to investors

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced it intends to offer $225 million aggregate principal amount of its convertible senior notes due 2024 in a private placement to... Read More

Thursday August 8, 2019 0 comments Tags: Boulder, Clovis Oncology